Histamine-induced bronchospasm. Its reproducibility and usage in clinical evaluation of the sub-threshold bronchodilating dose of a new beta-agonist, KWD 2131.

Abstract

The reproducibility of the histamine challenge in seven asymptomatic patients with extrinsic asthma, provoked four times each with 1-2 weeks interval, was investigated. The method was thereafter used in order to find the sub-threshold bronchodilating dose of a new beta-agonist KWD 2131 with a preferably anti-allergic property. Selection of patients and methodology of the histamine challenge procedure were carefully standardized. Histamine was administered during quiet breathing at 3-min intervals in a step-wise cumulative manner up to a point where greater than 20% decrease in FEV 1.0 was reached. The pooled intra-individual standard deviation was 4.6% in FEV 1.0, 5.0% in PEFR, and 4.7% in FVC. Pretreatment with KWD 2131, before histamine challenge, showed that the subthreshold dose for bronchodilatation was 0.5 mg in nine patients and 0.25 mg in three patients compared with 1 mg in patients with intrinsic asthma. It was important to perform individualized dose-titration of the sub-threshold bronchodilating dose of KWD 2131 before initiation of a subsequent allergen provocation study.

• Authors: B Hegardt, O Löwhagen, N Svedmyr
• Journal: Allergy (Allergy) Vol. 35 Issue 2 Pg. 113-21 (Mar 1980) ISSN: 0105-4538 [Print] Denmark
• PMID: 6104452 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Adrenergic beta-Agonists
• Bronchodilator Agents
• KWD 2131
• Histamine
• Terbutaline

Topics

• Adrenergic beta-Agonists (administration & dosage, therapeutic use)
• Adult
• Asthma (drug therapy)
• Bronchial Provocation Tests
• Bronchial Spasm (chemically induced)
• Bronchodilator Agents (therapeutic use)
• Clinical Trials as Topic
• Dose-Response Relationship, Drug
• Female
• Forced Expiratory Volume
• Histamine
• Humans
• Male
• Middle Aged
• Terbutaline (administration & dosage, analogs & derivatives, therapeutic use)